Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have received an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $14.30.

A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. HC Wainwright reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, June 4th. Truist Financial assumed coverage on Vanda Pharmaceuticals in a research report on Thursday, March 5th. They set a “buy” rating and a $18.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Monday, April 20th.

Vanda Pharmaceuticals Trading Down 0.8%

Shares of VNDA stock opened at $5.95 on Wednesday. The company has a market cap of $357.77 million, a PE ratio of -1.47 and a beta of 0.62. Vanda Pharmaceuticals has a 1 year low of $4.14 and a 1 year high of $9.94. The stock’s 50 day simple moving average is $6.44 and its two-hundred day simple moving average is $7.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.16 and a quick ratio of 2.15.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.13). The company had revenue of $51.72 million during the quarter, compared to the consensus estimate of $54.98 million. Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%. Research analysts predict that Vanda Pharmaceuticals will post -2.27 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its holdings in shares of Vanda Pharmaceuticals by 11.2% in the 1st quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock worth $25,979,000 after buying an additional 378,598 shares during the period. Vanguard Group Inc. increased its position in Vanda Pharmaceuticals by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,587,139 shares of the biopharmaceutical company’s stock valued at $17,900,000 after purchasing an additional 14,336 shares during the period. AIGH Capital Management LLC increased its position in Vanda Pharmaceuticals by 37.6% during the 1st quarter. AIGH Capital Management LLC now owns 2,750,000 shares of the biopharmaceutical company’s stock valued at $19,002,000 after purchasing an additional 751,569 shares during the period. Millennium Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 220.0% in the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after purchasing an additional 1,470,898 shares in the last quarter. Finally, Krensavage Asset Management LLC lifted its position in shares of Vanda Pharmaceuticals by 15.2% in the 3rd quarter. Krensavage Asset Management LLC now owns 1,180,388 shares of the biopharmaceutical company’s stock worth $5,890,000 after purchasing an additional 155,505 shares during the period. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.